SEC Form 4 · accession 0001177648-19-000028
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Golumbeski
Director
Period of report
Mar 4, 2019
Accepted (ET)
Mar 6, 2019 · 4:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 4, 2019 | M | 9,280 | $36.61 | A | 9,280 | D | |
| Common Stock | Mar 4, 2019 | S | 9,280 | $103.6527 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $36.61 | Mar 4, 2019 | M | 9,280 | D | — | Feb 7, 2024 | Common Stock | 9,280 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2018.
- F2100% of the shares subject to the option are fully vested and exercisable.